ARE YOUR PATIENTS ELIGIBLE FOR TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?
Please see most common responsive mutations below.
Mutations were considered responsive if net chloride transport increased by ≥10% of normal over baseline after
aThese mutations are present in ≥0.6% of individuals with CF.2